Clinical trial
Evaluation of the Predictive Value of Early Serum Trough Concentrations and Anti-drug Antibodies of Secukinumab and the Development of a Concentration Response Curve of Secukinumab for Psoriasis Patients.
NCT04080661 is registered in ClinicalTrials.gov with University Hospital, Ghent as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Evaluation of the Predictive Value of Early Serum Trough Concentrations and Anti-drug Antibodies of Secukinumab and the Development of a Concentration Response Curve of Secukinumab for Psoriasis Patients.
- Lead sponsor
- University Hospital, Ghent
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- March 22, 2018
- Completion date
- December 31, 2023
- Enrollment
- 82 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
psoriasis vulgaris